An interventional study of Nimodipine and Isotonic Saline in Colectomy, Open Surgery and Pain, sponsored by University of Ioannina. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by University of Ioannina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Pain with a site in Greece — 9 open to participants now, 9 under way, none of them phase 3. Pain · Greece.
Among the 38 studies in Pain with a site in Greece, this one is the 24th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, and was the 32nd registered.
10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.
Browse Pain studies →9 of the 38 studies in Pain with a site in Greece are open now. Recruiting first, the newest first:
University of Thessaly · Sites in Greece
Ages 18+
Aristotle University Of Thessaloniki · Sites in Greece
Ages 18–45 · Healthy volunteers
National and Kapodistrian University of Athens · Sites in Greece
Ages 18–80
Dionyssiotis, Yannis, M.D. · Sites in Greece
Ages 20–85 · Healthy volunteers
National and Kapodistrian University of Athens · Sites in Greece
Ages 18–79 · Women only
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 6 · Phase 4 3
First in 2003; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 66 across 8,512 interventional studies indexed under Pain.
Median enrollment 70 across the 31 interventional studies, 87 across the 7 observational. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 38 have an industry lead sponsor. The 10 most frequent:
University of Ioannina is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
University of Ioannina has 2 studies filed under Pain — fewer than ten, so there is no comparison to draw.
5 of the studies in Pain with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048522University of IoanninaPerioperative Intravenous Nimodipine Trial | 2026-12-19 |
| NCT07306312University of ThessalyPsychological Predictors of Pain and Disability in Patients With Chronic Low Back Pain After Manual Therapy | 2026-12-31 |
| NCT06791044Dionyssiotis, Yannis, M.D.25(OH)-Vitamin D and Its Association With Structural and Functional Parameters in Hospitalized Patients With Neurological Diseases | 2027-06 |
| NCT07901582National and Kapodistrian University of AthensImplementation of a Pain Management Plan in Major Open Abdominal Surgeries. | 2027-09-20 |
| NCT07863232University of ThessalyMelatonin and Immunonutrition for Pain Relief in Fibromyalgia | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 38 studies in Pain with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The role of perioperative IV administration of nimodipine, an L-type calcium channel antagonist which is capable of crossing the blood-brain barrier, on peri-operative opioid and anesthetics requirements, pain intensity, opioid-related side effects and early postoperative bowel mobility in patients undergoing surgical treatment for bowel cancer with open radical colectomy remains scarcely explored. A prospective double-blind, randomized controlled trial investigating the effect of perioperative IV administration of nimodipine in patients undergoing open colectomy for cancer treatment is therefore conducted.
Background with aim: Acute postoperative pain is still of major clinical concern for a large number of patients undergoing surgery worldwide. Despite advances in pain management strategies, many patients continue to suffer from moderate-to-severe pain during the early postoperative period, while opioids are still largely over-prescribed. Not effectively and especially unrelieved pain can result in decreased patient satisfaction, increased morbidity, prolonged hospital length-of-stay and increased risk of persistent pain. Furthermore, effective treatment of acute postoperative pain using opioid analgesics remains the core treatment for postoperative pain. Although the potential benefits of opioid therapy for acute pain lead to a short-term pain control there are several potential severe side-effects associated with opioid use which may outweigh the benefits including sedation, nausea, vomiting, constipation especially in bowel surgery, and the risk of long-term use. Although various non-opioid drugs have been investigated over the past decades, information regarding L-type calcium channel blockers in acute postoperative pain is limited. In this respect, the perioperative use of nimodipine, a drug which furthermore crosses the blood-brain barrier and has direct effects on the Central Nernous System (CNS) could potentiate the effects of opioid analgesia and intraoperative anesthetic requirements, providing improved analgesia and potentially reduce for opioids in the perioperative period. Therefore, the investigators decided to carry out the present study with the aim to examine the analgesic efficacy and safety of perioperatively administered IV nimodipine in patients undergoing open colectomy on perioperative opioid and anesthetic consumption, pain intensity, opioid-related side effects and early postoperative bowel mobility.
Method: A power analysis based on a previous preliminary study using IV nimodipine for medium risk general surgery (open cholecystectomy) showed that 9 patients would provide a power greater than 0.9 (α = 0.05) for detection of differences of pain scores and cumulative opioid consumption over time (up to 48 h). Therefore, 40 patients undergoing open colectomy will be included in this prospective, randomized, double-blind, controlled trial with two arms: an intervention arm (IV nimodipine 2 mg/h [10 ml/h] starting 1 h prior to surgery and continuing until 24 h after the end of the procedure) and a control arm (isotonic saline 10 ml/h starting 1 h prior to surgery and continuing until 24 h after the end of the procedure). The study is approved by the local hospital scientific board (#18-4_2024-12-05).
Hypothesis: The investigators hypothesize that perioperative intravenous administration of nimodipine, an L-type calcium channel antagonist, will be effective in reducing intraoperative anesthetic requirements, as well as intra- and postoperative opioid requirements, as well as postoperative pain intensity and opioid-related side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prepared (coded) by the pharmacy 50 ml solutions of nimodipine (2 mg/10 ml) with blinded 50 ml syringes will be used in each patient.
Drug: Nimodipine
Prepared (coded) by the pharmacy 50 ml solutions with blinded 50 ml syringes of isotonic saline will be used in each patient.
Drug: Isotonic Saline
A continuous dose of 2 mg/h (10 ml/h) of nimodipine solution will be administered continuously one (1) h prior to start of operation until 24 h after the end of the procedure.
A continuous dose of 10 ml/h of normal saline solution will be administered continuously one (1) h prior to start of operation until 24 h after the end of the procedure.
Intraoperative Remifentanil Consumption
Remifentanil will be administered intraoperatively based on qNOX (quantum NOXious stimulus index) levels, which will be maintained between 40 and 60. qNOX values below 40 will prompt a reduction in remifentanil dosing, while values above 60 will prompt an increase, in order to optimize analgesia.
Time frame: Intraoperative period, defined as the time (in minutes) from induction of general anesthesia to extubation.
Intraoperative propofol consumption
Propofol will be administered intraoperatively based on BIS (Bispectral Index) and qCON (quantum Consciousness Index) values, which will be maintained between 40 and 60. BIS or qCON values below 40 will prompt a reduction in propofol dosing, while values above 60 will prompt an increase, in order to maintain appropriate depth of anesthesia.
Time frame: Intraoperative period, defined as the time (in minutes) from induction of general anesthesia to extubation.
Cumulative opioid consumption within 0 to 72 hours postoperatively
Cumulative morphine consumption (mg) during the first 72 hours after arrival at the Post Anesthesia Care Unit (PACU). During the first hour in the PACU, morphine will be administered using a titration method. Following transfer to the surgical ward, a patient-controlled analgesia (PCA) device will be used to monitor morphine consumption. Cumulative opioid use will be recorded at specific time points: 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 hours postoperatively.
Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.
Pain intensity at rest
Pain intensity at rest will be assessed using the Numerical Rating Scale (NRS; 0-10), starting upon arrival at the Post Anesthesia Care Unit (PACU) and continuing at the following postoperative time points on the ward: 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 hours.
Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.
Pain intensity during coughing
Pain intensity during coughing will be assessed using the Numerical Rating Scale (NRS; 0-10), beginning upon arrival at the Post Anesthesia Care Unit (PACU) and at the following postoperative time points on the ward: 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 hours.
Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.
Opioid related sedation
Number of participants with postoperative sedation assessed using the Ramsay Sedation Scale (range: 1 = anxious/agitated to 6 = no response to stimulus).
Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.
Opioid related pruritus
Number of participants with documented pruritus related to opioid use, recorded as a binary outcome variable (yes/no).
Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.
Postoperative nausea and/or vomiting (PONV)
Number of participants with documented postoperative episodes of nausea and/or vomiting, recorded as a binary outcome variable (yes/no).
Time frame: From Post Anesthesia Care Unit (PACU) admission (time zero) to 72 hours postoperatively.
Time to first signs of bowel mobilization
Time (in hours) from the end of surgery to the first documented sign of bowel function, defined as either the first bowel sounds on auscultation or the first passage of flatus. Assessment will take place in the surgical ward at the following postoperative time points: 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, and 90 hours, or until hospital discharge, whichever comes first.
Time frame: From end of surgery to 90 hours postoperatively or until hospital discharge, whichever comes first.
Length of stay (LOS)
Total duration of hospitalization, measured in days from admission to discharge.
Time frame: Duration of hospitalization, from the day of admission to the day of discharge (up to 30 days).
Plan to share: No — The data will be shared upon reasonable request by other researchers
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 19 months is above that.
Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nimodipine
University of Ioannina